We have now received an appointment letter from Great Ormond Street Hospital in London for October 18, 2012 to take our children there in order to get a detailed genetic consultation, physiotherapy assessment, and to talk about Exon skipping plan based on results of biopsy for genes molecular diagnosis and its management.

FORBES: The Cities With The Happiest Young Professionals

But Sarepta is working on other exon-skipping drugs that skip exon 45 and exon 50, which could help 9% and 5% of Duchenne patients, respectively.

FORBES: In A First, An Experimental Drug May Help Boys With Muscular Dystrophy

Eighty-five percent of Duchenne patients have the exon-skipping gene.

FORBES: In A First, An Experimental Drug May Help Boys With Muscular Dystrophy

Another exon 51-skipping drug, developed by Prosensa, a Dutch biotech, and partner GlaxoSmithKline, is expected to have results from a large study later this year.

FORBES: In A First, An Experimental Drug May Help Boys With Muscular Dystrophy